glp 1 drugs and pancreatitis Suspected drug-induced was rare but more common in patients taking GLP-1 agonists than sulfonylureas, a recent analysis of a VA database finds Studies examining GLP-1 RA therapy

Folli F, Guardado MR

[DOI] [PubMed] [Google Scholar] 99.Knop F.K., Aroda V.R., do Vale R.D., Holst-Hansen T., Laursen P.N., Rosenstock J., Rubino D.M., Garvey W.T., OASIS 1 Investigators Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial

Exp Dermatol 22(2):150152 Jensen P, Skov L (2016) Psoriasis and obesity

Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary The GLP-1 agonists market in the 7MM is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan)

Heres what to consider: Gradual transition : If discontinuing GLP-1 receptor agonists, do so under medical supervision to prevent rapid weight regain

Differentiation in GLP-1 Products *Weight-related comorbidities may include but are not limited to hypertension, dyslipidemia, CVD, sleep apnea, and T2D